BTIG Maintains Buy on Carlsmed, Raises Price Target to $24
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.
Share
Why It Matters
A stock expert thinks Carlsmed is still a good company to own. They raised their price guess by one dollar, showing they feel a bit more confident.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.